ProCE Banner Activity

ZUMA-3: Phase II Results With Brexucabtagene Autoleucel for Relapsed/Refractory Adult B-Cell ALL

Slideset Download
Conference Coverage
Brexucabtagene autoleucel produced durable, high rates of response in relapsed/refractory adult B-cell ALL with no unexpected safety signals.

Released: June 08, 2021

Expiration: June 07, 2022

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

Amgen, Inc.

AstraZeneca

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis

Gilead Sciences, Inc.

GlaxoSmithKline

Ipsen Biopharmaceuticals Inc

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Pfizer, Inc.

Pharmacyclics LLC an AbbVie Company and Janssen Biotech Inc

Sanofi Genzyme